

## THE POWER OF IMAGERY IN CLINICAL MEDICINE: LEVERAGING CLINICAL PHOTOS FROM THE VISIBLE STUDY TO FOSTER CONVERSATIONS BETWEEN CLINICIANS AND PATIENTS



Adrian O Rodriguez, Linda Stein Gold, Mona Shahriari, Andrew Alexis, Olivia Choi, Daphne Chan, Theodore Alkousakis, Elizabeth Skobelev, Sancharitha Ramji, Amy McMichael, Susan C Taylor, Seemal R Desai


<sup>1</sup>Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA; <sup>2</sup>Henry Ford Medicine, New York, NY, USA; <sup>3</sup>Yale University School of Medicine, Central Connecticut Dermatology, New Haven, CT, USA; <sup>4</sup>Weill Cornell Medicine, New York, NY, USA; <sup>5</sup>Johnson & Johnson, Horsham, PA, USA; <sup>6</sup>Wake Forest School of Medicine, Winston-Salem, NC, USA; <sup>7</sup>Perelman Center for Advanced Medicine, Philadelphia, PA, USA; <sup>8</sup>University of Texas Southwestern and Innovative Dermatology, Plano, TX, USA

#### **BACKGROUND/OBJECTIVE**

- Psoriasis (PsO) is often described as well-defined, inflamed, red or pink plaques with scaling; however, in individuals with skin of color (SOC), this description is not always accurate<sup>1,2</sup>
- Only 4–19% of images in dermatology textbooks are on darker skin tones<sup>3</sup>
- VISIBLE (NCT05272150) evaluated efficacy of guselkumab (GUS) versus placebo (PBO) in participants (pts) with moderate-to-severe plaque PsO or scalp PsO in SOC
- As a first-of-its-kind study 100% dedicated to people of color with PsO, VISIBLE enabled the development of a digital photo library to address the clinical knowledge gap for visualizing PsO in a range of skin tones; here we present a snapshot of this tool
- To compile a PsO digital photo library from VISIBLE clinical trial pts with a range of skin tones
- To educate providers and patients on the clinical features of PsO in all skin tones
- To improve diagnostic accuracy of PsO across all skin tones

measurement of non-sun-exposed skin)


# **METHODS: THE VISIBLE STUDY**



visualization

- Pts in the trial gave consent for the medical use of their photos
- Photography was done using standard and cross-polarized lighting; cross-polarization enhances visualization of erythema and pigmentation, especially in SOC
- Standard positions were used for body and scalp photos, with software assistance to match positioning between visits
- The protocol included photo collection at screening and Weeks 0, 4, 12, 16, 20, 24, 32, 44, 48, 52, 68, 84, and 100

#### **VISIBLE REPRESENTS A DIVERSE POPULATION ACROSS SKIN TONES**



**EXPANDING THE PSORIASIS DIFFERENTIAL** Psoriasis may be more challenging to diagnose on diverse skin tones because it may require a broader differential, which may explain when it is 4x more likely to require a biopsy for diagnosis of skin of color<sup>4</sup> These are photos that do not fit the classic morphology description of "well-demarcated erythematous plaque with silvery scale" Differential Diagnosis may include: • Lichen Planus Tinea Versicolor Atopic Dermatitis • Pityriasis Rubra Pilaris Crusted Scabies Drug Eruption • Erythema Dyschromicum Perstans

### **PSORIASIS MORPHOLOGY MAY VARY ACROSS SKIN TONES**

Back

- Morphology descriptors include: color (violaceous, brown, pink, etc.), scale (ostracoeus, micaceous, thick, etc.), size (large, agminated small plaques, confluent, etc.)
- Cross-polarization can enhance erythema and pigmentation in SOC



#### HCPs can filter the search criteria to explore subsets of Health Care Professionals (HCPs) and patients can find the most searched for PsO manifestations or browse curated PsO images libraries of images Browser Photo My Fevorite Features About the Database My Account Apply filters to search for specific images based on: • Skin Tone Disease Severity Special Site Pigmentation Body Part • Gender Morphology Age At Week 48, th

PHOTO LIBRARY INTERFACE ELEMENTS

#### **CONCLUSIONS**

- The first-of-its-kind VISIBLE study recruited a diverse population of pts with moderate-to-severe plaque PsO across all skin tones and was intentionally designed to collect standardized serial photos to help address the dearth of photos of darker skin tones in medical and educational materials
- VISIBLE pts' Ps0:
- ranged in color from traditional erythematous spectrum to violaceous and brown
- exhibited diverse morphology ranging from small, scattered plaques, to large, thin, or very thick plaques, with varied scale features even within the same pt
- exhibited a broader differential for psoriasis across diverse skin tones because of the variations in color and morphology
- The VISIBLE study starts a photo library that is an expandable, searchable, digital platform for bridging education gaps around treating those currently underrepresented

PRESENTED AT: Winter Clinical Dermatology Conference - Hawaii 2025; Waikoloa Village, HI, USA; February 14-19, 2025. References: 1. Khanna R, et al. Dermatol Clin. 2023;41(3):431–34. 2. Kaufman BP, et al. Dermatol Clin. 2023;41(3):405–23. 3. Bellicoso E, et al. Dermatol Clin. 2023;41(3):431–34. 2. Kaufman BP, et al. Dermatol Clin. 2023;41(3):431–34. 3. Bellicoso E, et al. Dermatol Clin. 2023;41(3):431–45. 3. Bellicoso E, et al. Dermatol Clin. 2023;4 Novartis, Ortho Dermatologics, Regeneron, Sanofi-Genzyme, Takeda, and UCB; aerved as a speaker for AbbVie, Arguits, Pfizer, and UCB; ara for AbbVie, Arguits, Pristol Myers Squibb, Dermavant, Dermaton, Sanofi-Genzyme, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as a served as an investigator for AbbVie, Arguits, Prizer, and UCB; and served as a served a consultant and/or speaker for AbbVie, Arcutis, Armis, Avita, Beiersdorf, Biorez, Bristol Myers Squibb, Cara, Dior, Eli Lilly, and Pfizer. PREVIOUSLY PRESENTED AT: Fall (author/royalties), Honoraria/Board of Directors), McGraw-Hill (author/royalties), editorial board: Practical Dermatology, Cutis, Archives in Dermatol